Overview
Cybin is a clinical-stage biopharmaceutical company developing proprietary psychedelic-based therapeutics, with lead programs targeting major depressive disorder using deuterated psilocybin analogs engineered for improved pharmacokinetics. Their CYB003 and CYB004 molecules are designed to provide more predictable and shorter therapeutic sessions.
More in Psychedelics
Latest industry news
ReVision Implant Secures €4 Million to Advance Next-Generation Visual Neuroprosthetics
2026-07-25 · Funding
Flourish Emerges from Stealth with Bezos and Google Ventures Backing to Advance Neuroscience Therapeutics
2026-07-24 · Funding
Science Corp. Launches Prima BCI Implant in Europe, Bringing Vision Restoration to a New Market
2026-07-23 · Product
First Able-Bodied Individuals Receive Brain-Computer Implants in Landmark Expansion of BCI Eligibility
2026-07-22 · Research
Company details
Category
🍄 Psychedelics
Location
Toronto, Canada
Funding
Public · NYSE American: CYBN
Website
www.cybin.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →